{"disease":{"id":"influenza-a-virus","name":"influenza a virus"},"drugs":{"marketed":[{"drug_id":"licensed-influenza-vaccine-3","indication_name":"Intranasal influenza vaccine for active immunization against influenza disease caused by influenza virus types A and B, in individuals 6 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Assorted Licensed Hand Sanitizer Grape 01","generic_name":"Licensed Influenza Vaccine 3","company_name":"BioNTech","drug_phase":"marketed","molecular_target":"Influenza virus hemagglutinin protein","drug_class":"Vaccine","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"flu-vaccine","indication_name":"Prevention of influenza caused by virus subtypes A and B contained in the vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Flu Vaccine","company_name":"La Fundacion Favaloro para la Investigacion y la Docencia Medica","drug_phase":"marketed","molecular_target":"Influenza A and B viral hemagglutinin and neuraminidase surface antigens","drug_class":"Prophylactic vaccine","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-modrna-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quadrivalent influenza modRNA vaccine","generic_name":"quadrivalent-influenza-modrna-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Vaccine","quality_score":52,"revenue":null,"mechanism":"This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses."},{"drug_id":"quadrivalent-influenza-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in people 6 months of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Quadrivalent Influenza Vaccine","company_name":"International Centre for Diarrhoeal Disease Research, Bangladesh","drug_phase":"marketed","molecular_target":"Influenza viruses","drug_class":"Inactivated vaccine","quality_score":34,"revenue":null,"mechanism":"This vaccine works by stimulating the body's immune system to produce antibodies against influenza viruses."},{"drug_id":"quadrivalent-influenza-vaccine","indication_name":"Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in people 6 months of age and older, when the circulating influenza A and B viruses are expected to be well matched to the vaccine viruses.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Quadrivalent Influenza Vaccine","company_name":"International Centre for Diarrhoeal Disease Research, Bangladesh","drug_phase":"marketed","molecular_target":"Influenza viruses","drug_class":"Inactivated vaccine","quality_score":34,"revenue":null,"mechanism":"This vaccine works by stimulating the body's immune system to produce antibodies against influenza viruses."},{"drug_id":"amantadine","indication_name":"Influenza due to Influenza A virus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gocovri","generic_name":"AMANTADINE","company_name":"Endo","drug_phase":"marketed","molecular_target":"Sigma non-opioid intracellular receptor 1","drug_class":"Influenza A M2 Protein Inhibitor","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"favipiravir","indication_name":"Influenza caused by pandemic influenza virus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avigan","generic_name":"FAVIPIRAVIR","company_name":"Toyama Chemical Co., Ltd.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"qiv","indication_name":"Prevention of influenza A virus, A(H1N1)pdm09, A(H3N2), and influenza B viruses","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Qiv","generic_name":"qiv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza viruses","drug_class":"Inactivated vaccine","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"gocovri","indication_name":"Influenza due to Influenza A virus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"GOCOVRI","company_name":"Oregon Health and Science University","drug_phase":"marketed","molecular_target":"Sigma non-opioid intracellular receptor 1","drug_class":"Influenza A M2 Protein Inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"amantadin","indication_name":"Influenza due to Influenza A virus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amantadin","company_name":"Centre Hospitalier Universitaire de Nice","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Sigma non-opioid intracellular receptor 1, Glutamate [NMDA] receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":60,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03294473","title":"Centralized Reminder Recall - Flu RCT2","phase":"NA","overall_status":"COMPLETED","enrollment_count":70190,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT06207929","title":"Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Between Passively-collected Data From Wearable Activity Devices and Respiratory Viral Infections","phase":"","overall_status":"COMPLETED","enrollment_count":18157,"lead_sponsor_name":"Evidation Health","has_results":false},{"nct_id":"NCT06229444","title":"Predict + Protect Study: Exploring the Effectiveness of a Predictive Health Education Intervention on the Adoption of Protective Behaviors Related to ILI","phase":"NA","overall_status":"COMPLETED","enrollment_count":17043,"lead_sponsor_name":"Evidation Health","has_results":false},{"nct_id":"NCT07358910","title":"Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Institut Pasteur du Cambodge","has_results":false},{"nct_id":"NCT03870061","title":"Evaluation of an Infant Immunization Encouragement Program in Nigeria","phase":"NA","overall_status":"COMPLETED","enrollment_count":5187,"lead_sponsor_name":"GiveWell","has_results":false},{"nct_id":"NCT06821061","title":"A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":2650,"lead_sponsor_name":"BioNTech SE","has_results":false},{"nct_id":"NCT04074928","title":"Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2414,"lead_sponsor_name":"Seqirus","has_results":true},{"nct_id":"NCT04288921","title":"Evaluation of Performance of the LumiraDx Influenza A/B + RSV Test at POC Testing Sites","phase":"NA","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"LumiraDx UK Limited","has_results":false},{"nct_id":"NCT07217639","title":"Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Aptitude Medical Systems","has_results":false},{"nct_id":"NCT05277298","title":"Household Study of COVID-19, Influenza and RSV Burden, Transmission Dynamics and Viral Interaction in South Africa","phase":"","overall_status":"UNKNOWN","enrollment_count":1200,"lead_sponsor_name":"National Institute for Communicable Diseases, South Africa","has_results":false},{"nct_id":"NCT04772170","title":"Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT06392451","title":"LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"DiaSorin Molecular LLC","has_results":false},{"nct_id":"NCT04527614","title":"Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection","phase":"NA","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Sciensano","has_results":false},{"nct_id":"NCT06401720","title":"Age Related Differences in Respiratory Immune Responses in Influenza Virus Infection","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":800,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT05071313","title":"A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":777,"lead_sponsor_name":"Janssen Vaccines & Prevention B.V.","has_results":true},{"nct_id":"NCT03497845","title":"Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":720,"lead_sponsor_name":"Biomedical Advanced Research and Development Authority","has_results":true},{"nct_id":"NCT06842173","title":"Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Butantan Institute","has_results":false},{"nct_id":"NCT05875961","title":"Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Seqirus","has_results":false},{"nct_id":"NCT05874713","title":"Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":480,"lead_sponsor_name":"Seqirus","has_results":false},{"nct_id":"NCT04429295","title":"Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":460,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT03392207","title":"Active Surveillance for Adverse Events Following Immunization With the Butantan Trivalent Influenza Vaccine (2018)","phase":"","overall_status":"COMPLETED","enrollment_count":403,"lead_sponsor_name":"Butantan Institute","has_results":false},{"nct_id":"NCT05794412","title":"Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational Study","phase":"","overall_status":"COMPLETED","enrollment_count":320,"lead_sponsor_name":"University Hospital, Geneva","has_results":false},{"nct_id":"NCT07275060","title":"Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":312,"lead_sponsor_name":"Canadian Immunization Research Network","has_results":false},{"nct_id":"NCT05397223","title":"A Study of Modified mRNA Vaccines in Healthy Adults","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":308,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT07393685","title":"Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Tianjin Medical University","has_results":false},{"nct_id":"NCT06850051","title":"A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":270,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05422326","title":"A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":260,"lead_sponsor_name":"Seqirus","has_results":false},{"nct_id":"NCT03757546","title":"Extra-pulmonary Clinical Manifestations of Influenza Virus and Respiratory Syncitial Virus Infections","phase":"","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"Poitiers University Hospital","has_results":false},{"nct_id":"NCT05897515","title":"LIAISON NES Influenza (FLU) A/B & Coronavirus Disease 2019 (COVID-19) Clinical Agreement in Australia","phase":"NA","overall_status":"COMPLETED","enrollment_count":233,"lead_sponsor_name":"DiaSorin Molecular LLC","has_results":false},{"nct_id":"NCT02532283","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT05375006","title":"Tropism and Pathogenesis of Influenza Virus and Coronavirus in Human Brain Explant Culture","phase":"","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT01086657","title":"An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT00646152","title":"Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT06684379","title":"Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"PEACHES BIOTECH","has_results":false},{"nct_id":"NCT04110366","title":"Nasal and Systemic Immune Responses to Nasal Influenza Vaccine","phase":"NA","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Imperial College Healthcare NHS Trust","has_results":true},{"nct_id":"NCT00408109","title":"Safety Study of Avian Flu Vaccine","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT00489931","title":"Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03651544","title":"The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","has_results":false},{"nct_id":"NCT07215871","title":"Rechallenge With a Low Pathogenicity Avian H10N7 Influenza Virus in Healthy Human Volunteers Previously Challenged With H10N7 Influenza","phase":"PHASE1","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":33,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT00973895","title":"VRC 308: An Open-Label Phase I Study of the Safety and Immunogenicity of an Investigational H1 DNA Influenza Vaccine, VRC-FLUDNA057-00-VP, in Healthy Adults 18-70 Years Old","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT00989404","title":"Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT04896853","title":"Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":9,"lead_sponsor_name":"NextCell Pharma Ab","has_results":false},{"nct_id":"NCT04664075","title":"Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19)","phase":"","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Imperial College London","has_results":true},{"nct_id":"NCT04431050","title":"Evaluation of a Single Use Point of Care Device for the Diagnosis of Respiratory Pathogens","phase":"","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Imperial College London","has_results":true},{"nct_id":"NCT03924284","title":"Novel Assays for Detection of Influenza Virus","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT03834376","title":"Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A Infection","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false}],"total":46},"guidelines":[],"source":"Drug Landscape verified database"}